The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
about
Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistancePlasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic TestingUrokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applicationsTumor Associated Macrophages in Kidney CancerInterleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expressionIdentification of uPAR-positive chemoresistant cells in small cell lung cancerDependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of SerpinE1 and SerpinB2 in cancer.Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patientsPrognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycleHigh TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.microRNA-200c/141 upregulates SerpinB2 to promote breast cancer cell metastasis and reduce patient survival.Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR)Expression of proteinases and inhibitors in human breast cancer progression and survival.TFRC and ACTB as the best reference genes to quantify Urokinase Plasminogen Activator in breast cancerFree fatty acids enhance breast cancer cell migration through plasminogen activator inhibitor-1 and SMAD4Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditionsThe hemostatic system and angiogenesis in malignancy.External validation of a Cox prognostic model: principles and methodsRole of genetic polymorphisms in tumour angiogenesisPrognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasisIn vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancerImpaired MicroRNA Processing Facilitates Breast Cancer Cell Invasion by Upregulating Urokinase-Type Plasminogen Activator ExpressionMatrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis.Down-regulation of survivin suppresses uro-plasminogen activator through transcription factor JunBClinical significance of miR-140-5p and miR-193b expression in patients with breast cancer and relationship to IGFBP5.Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms.Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor.Involvement of hypoxia-inducing factor-1alpha-dependent plasminogen activator inhibitor-1 up-regulation in Cyr61/CCN1-induced gastric cancer cell invasion.Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity.Unmanipulated native fat exposed to high-energy diet, but not autologous grafted fat by itself, may lead to overexpression of Ki67 and PAI-1.Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221.Protease-activated drug development.Peptide-Based Optical uPAR Imaging for Surgery: In Vivo Testing of ICG-Glu-Glu-AE105Stroma targeting nuclear imaging and radiopharmaceuticals.uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor.First-in-human uPAR PET: Imaging of Cancer Aggressiveness.RA-XII inhibits tumour growth and metastasis in breast tumour-bearing mice via reducing cell adhesion and invasion and promoting matrix degradation.
P2860
Q24642804-AF1D9C58-C718-405B-BBAC-4D288825A624Q26801060-C2035A8F-755E-4239-A665-113600CA0500Q26865306-E21EDD6C-AFEF-4FB1-BC3C-DC336A66F673Q28071990-DE8320D8-804B-4BF2-B321-2B2F7B12F88FQ28390678-A876CF1D-40CF-4308-AE79-17EDCFB17E44Q28469143-3DA00D40-EB42-4FEB-8AFE-07F008973616Q30502082-EE42E232-6FB2-4C8D-98B4-56E00DDCF61FQ31021361-22E66843-2FF2-47C1-BFAB-BB6B086201C8Q33255953-9505888B-9CDB-461E-AB19-A04A9FFAEF58Q33698446-C492130C-9A09-463D-8E12-0D933F0A679FQ33715393-9D532433-8977-4192-91A5-A5A92C204799Q33739228-349FAF20-8804-40D1-B167-22C465993D9CQ33779244-6ADCB5DF-9BBC-4364-9E1F-FC104F704E56Q33912826-4E02086B-36FA-497A-8288-A47E0A94105DQ33919059-7C2972CA-8CF9-4799-9F04-69F37D662AB6Q33942462-4E4DCDAB-1310-49A2-A1C1-4C4CEDEAE977Q34000430-59027C93-2931-4BCC-81B6-E229BF0D832BQ34217461-35886266-EA05-4FF9-8664-9613B671EC30Q34425462-7A8E9F3B-950E-4AA8-B6F9-FDFBC4B5DE45Q34621957-EE279FAC-9E3C-43F6-BE8D-E04BE0A32A05Q34981278-D3F5183C-B9BF-4A8F-88DF-A43C9729793BQ34995476-C9640329-45F3-4FE8-B30F-C833367B72DBQ34997475-F9A7D47B-0AAB-4A0D-B116-C8E5CB875DC2Q35034871-8D6F002D-B511-4E11-8588-7415C14E49F4Q35159014-B433B535-F975-427B-8DBE-4D1FA6B9978FQ35463910-DDDDDCB7-BD22-4F5B-AD91-36C6CD28AF80Q35556972-9095ABEF-547D-400A-92B4-D0EA6188B51AQ35596926-631B8A38-13EC-4DD1-B3AD-C8DAEC3CBE0FQ35604600-3A6E5EC6-8316-4B37-8D13-816E8C9BE518Q35676352-AA4953F5-8790-4BFC-9D57-2AD641FDDBB6Q35711136-0B6AF8C7-DD6F-487C-952A-2B36BBA9E12BQ35752791-E3BED56C-C13F-420F-8C12-01C28C28AC06Q35781516-DF5A260F-0761-4D35-9EF5-0DA7662BF22EQ35811508-70D80FC6-0A7E-461B-91FA-F1ECC6ADBDB1Q35909379-1362DAE5-16DD-4226-A9DB-39C79BFAA01DQ35999606-13ECF40E-5DB1-4DA0-AEA3-9F0904DC4E54Q36097941-6F12D80B-2667-4A4D-BD49-4EF9F0E8191BQ36143607-FEF48E7D-5E43-45A8-9794-6590DF4271D4Q36191589-A68E60BD-E40F-4F11-91D7-0AFD92A3EDD5Q36305387-A506500D-78B3-40EB-94CC-E87AFBEA60FB
P2860
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The urokinase system of plasmi ...... n 2780 breast cancer patients.
@ast
The urokinase system of plasmi ...... n 2780 breast cancer patients.
@en
type
label
The urokinase system of plasmi ...... n 2780 breast cancer patients.
@ast
The urokinase system of plasmi ...... n 2780 breast cancer patients.
@en
prefLabel
The urokinase system of plasmi ...... n 2780 breast cancer patients.
@ast
The urokinase system of plasmi ...... n 2780 breast cancer patients.
@en
P2093
P1433
P1476
The urokinase system of plasmi ...... n 2780 breast cancer patients.
@en
P2093
Foekens JA
Henzen-Logmans SC
Meijer-van Gelder ME
Portengen H
P304
P407
P577
2000-02-01T00:00:00Z